Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 85,943 |
|
|||||
| News | - | ||||||
| Day High | 0.91 | Low High |
|||||
| Day Low | 0.76 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Viracta Therapeutics Inc | VIRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.07 | 7.95% | 0.95 | 19:59:12 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.91 | 0.76 | 0.91 | 0.8478 | 0.88 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 306 | 85,943 | $ 0.8516746 | $ 73,195 | - | 0.43 - 2.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:55:47 | formt | 500 | $ 0.95 | USD |
Viracta Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 33.38M | 39.27M | - | 0 | -51.06M | -1.30 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Viracta Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VIRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7701 | 0.99 | 0.67 | 0.8322826 | 116,686 | 0.1799 | 23.36% |
| 1 Month | 1.11 | 1.31 | 0.67 | 0.9846537 | 150,448 | -0.16 | -14.41% |
| 3 Months | 0.54 | 1.31 | 0.5051 | 0.8836341 | 118,172 | 0.41 | 75.93% |
| 6 Months | 0.7448 | 1.31 | 0.43 | 0.6826659 | 141,939 | 0.2052 | 27.55% |
| 1 Year | 1.30 | 2.38 | 0.43 | 1.13 | 155,549 | -0.35 | -26.92% |
| 3 Years | 8.38 | 13.08 | 0.43 | 4.34 | 189,885 | -7.43 | -88.66% |
| 5 Years | 16.76 | 18.24 | 0.43 | 4.88 | 199,226 | -15.81 | -94.33% |
Viracta Therapeutics Description
| Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. |
